DFIB Cardiac Science (MM)

City of Miami Purchases AEDs for Police Vehicles Under Citywide PAD Program Purchase of Powerheart(R) AEDs for Public Access Defibrillation Program Valued at Over $200,000 IRVINE, Calif., April 11 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. (NASDAQ:DFIB), a leading manufacturer of public-access defibrillators (AEDs), today announced that the city of Miami purchased approximately 100 new fully- automatic version Powerheart(R) G-3 AEDs as part of its citywide Public Access Defibrillation Program (PAD). The $200,000 order for Miami's "Team for Life" PAD project follows the City's initial order last Fall for 42 Powerhearts that were deployed in city buildings and parks. The latest deployment of Powerhearts are earmarked principally for use in city police vehicles. Miami's PAD project is an exclusive public-private partnership between the city and Cardiac Science. The goal of the project, which is being coordinated by the Miami Department of Fire-Rescue, is to save lives and protect Miami citizens and visitors by making AEDs more accessible in a variety of settings throughout the city. The program includes comprehensive AED/CPR training and AED program management services and a citywide public awareness campaign on the importance of defibrillation therapy and the use of AEDs to treat victims of a massive heart attack, also called sudden cardiac arrest. The project began with Miami's selection of Cardiac Science last fall as the city's exclusive provider of AEDs. City officials stated that they plan to deploy Powerheart AEDs in police and fire vehicles as well as city facilities and other public locations where large numbers of people congregate. "We are working very closely with city officials in Miami to ensure their PAD program is as successful as the San Diego Project Heartbeat PAD program where over 1,200 Powerheart AEDs have been deployed since 2001 and dozens of lives have been saved as a result," said Cardiac Science Chairman and Chief Executive Officer Raymond W. Cohen. "We consider the partnership between Cardiac Science and Miami to be an excellent example of how cities can work with private industry to improve safety and public education. Everyone who lives in Miami or visits the city could benefit directly from the 'Team for Life' project." About Cardiac Science Cardiac Science develops, manufactures and markets a complete line of Powerheart(R) brand, automatic public access defibrillators (AEDs), and offers comprehensive AED/CPR training and AED program management services that facilitate successful deployments. The company makes the Powerheart(R) CRM(R), the only FDA-cleared therapeutic patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms. Cardiac Science also manufactures its AED products on a private label basis for other leading medical companies such as Nihon Kohden (Japan), Quinton Cardiology Systems and GE Healthcare. For more information please visit http://www.cardiacscience.com/ or call (949) 797-3800. This press release includes forward-looking statements. These statements may be identified by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. Cardiac Science has based these forward-looking statements on the current expectations, assumptions, estimates and projections. While Cardiac Science believes the City of Miami PAD project will lead to future purchases of AEDs and be a benefit to the city of Miami and it citizens, these expectations, assumptions, estimates and projections, while reasonable, are forward-looking statements and are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. Certain factors, including those discussed in Cardiac Sciences' Annual Report on Form 10-K for the year ended December 31, 2004, under the heading "Risk Factors," may cause the actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. We do not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments. Contact: Matt Clawson (Investors), or Michael Gioffredi Len Hall (Media) Chief Marketing Officer Allen & Caron Inc Cardiac Science, Inc. (949) 474-4300 (949) 797-3800 DATASOURCE: Cardiac Science, Inc. CONTACT: Matt Clawson (Investors), , or Len Hall (Media), , both of Allen & Caron Inc, +1-949-474-4300, for Cardiac Science, Inc.; or Michael Gioffredi, Chief Marketing Officer of Cardiac Science, Inc., +1-949-797-3800, Web site: http://www.cardiacscience.com/

Copyright